Work

Abstract LB-061: HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivo

Year: 2016

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2016-lb-061

Authors: Elena Geretti, Christopher Espelin, Bambang Adiwijaya, Nancy Dumont, Silvia Coma, Zachary Koncki, Minh Pham, Gabriela Garcia, Troy Bloom, Victoria Rimkunas, Joe Reynolds, Karen Campbell, Victor Moyo, Istvan Molnar, Patricia LoRusso, Ian Krop, Kathy Miller, Cynthia Ma, Pamela Munster, Thomas Wickham

Institutions: Merrimack Pharmaceuticals (United States), Yale Cancer Center, Yale University, Dana-Farber Cancer Institute, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Washington University in St. Louis, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Nanoparticle-Based Drug Delivery

Subfield: Biomaterials

Field: Materials Science

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2479692189

Cites:

Cited by:

Related to: 10